Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Exencial Wealth Advisors LLC

Exencial Wealth Advisors LLC lessened its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating) by 21.1% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 13,619 shares of the medical research company’s stock after selling 3,646 shares during the period. Exencial Wealth Advisors LLC’s holdings in Thermo Fisher Scientific were worth $9,087,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Widmann Financial Services Inc. acquired a new stake in Thermo Fisher Scientific during the 4th quarter valued at $26,000. Lee Financial Co acquired a new stake in Thermo Fisher Scientific during the 4th quarter valued at $32,000. Costello Asset Management INC acquired a new stake in Thermo Fisher Scientific during the 4th quarter valued at $33,000. Moors & Cabot Inc. raised its stake in Thermo Fisher Scientific by 319.3% during the 3rd quarter. Moors & Cabot Inc. now owns 25,000 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 19,037 shares during the period. Finally, Cranbrook Wealth Management LLC raised its stake in Thermo Fisher Scientific by 43.5% during the 3rd quarter. Cranbrook Wealth Management LLC now owns 66 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 20 shares during the period. Institutional investors own 87.48% of the company’s stock.

In other Thermo Fisher Scientific news, Director Debora L. Spar sold 200 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, May 2nd. The stock was sold at an average price of $544.36, for a total transaction of $108,872.00. Following the sale, the director now directly owns 810 shares of the company’s stock, valued at $440,931.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 2,181 shares of the company’s stock in a transaction that occurred on Wednesday, May 4th. The shares were sold at an average price of $562.46, for a total value of $1,226,725.26. Following the completion of the sale, the chief executive officer now owns 183,373 shares in the company, valued at $103,139,977.58. The disclosure for this sale can be found here. In the last quarter, insiders sold 13,881 shares of company stock valued at $7,637,522. 0.43% of the stock is owned by corporate insiders.

A number of equities analysts have recently weighed in on TMO shares. BTIG Research reaffirmed a “buy” rating and issued a $718.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, February 3rd. StockNews.com started coverage on shares of Thermo Fisher Scientific in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. Wells Fargo & Company downgraded shares of Thermo Fisher Scientific from an “equal weight” rating to an “underweight” rating and dropped their price target for the stock from $605.00 to $525.00 in a research note on Monday, April 25th. Zacks Investment Research downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and set a $609.00 price target on the stock. in a research note on Monday, January 24th. Finally, Barclays initiated coverage on shares of Thermo Fisher Scientific in a research note on Wednesday, January 26th. They issued an “overweight” rating and a $700.00 price target on the stock. One investment analyst has rated the stock with a sell rating, three have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $647.00.

TMO stock traded up $15.62 during mid-day trading on Friday, reaching $541.42. 1,375,157 shares of the stock traded hands, compared to its average volume of 1,562,349. The company has a quick ratio of 1.10, a current ratio of 1.56 and a debt-to-equity ratio of 0.77. Thermo Fisher Scientific Inc. has a 52 week low of $438.72 and a 52 week high of $672.34. The business has a 50-day moving average of $563.85 and a two-hundred day moving average of $593.15. The firm has a market capitalization of $211.94 billion, a PE ratio of 28.23, a P/E/G ratio of 1.76 and a beta of 0.83.

Thermo Fisher Scientific (NYSE:TMOGet Rating) last released its quarterly earnings results on Thursday, April 28th. The medical research company reported $7.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.20 by $1.05. Thermo Fisher Scientific had a net margin of 18.49% and a return on equity of 25.33%. The company had revenue of $11.82 billion during the quarter, compared to analysts’ expectations of $10.66 billion. During the same period in the prior year, the company earned $7.21 earnings per share. The business’s quarterly revenue was up 19.3% compared to the same quarter last year. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 22.68 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Thursday, April 14th. Investors of record on Wednesday, March 16th were paid a $0.30 dividend. This represents a $1.20 annualized dividend and a dividend yield of 0.22%. The ex-dividend date was Tuesday, March 15th. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.26. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 6.26%.

About Thermo Fisher Scientific (Get Rating)

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

See Also

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.